The role of genetics for biomarker development in neurodegeneration

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 501-504

  Bertram, Lars ^a   Hampel, Harald ^b  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Biomarker; Frontotemporal dementia; Genetic association; Genetic profiling; Genome wide association study; Genomic profiling; Neurodegenerative disease genetics; Parkinson's disease; Risk prediction

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL DEMENTIA; GENETIC ASSOCIATION; GENETICS; HUMAN; MEDICAL RESEARCH; NERVE DEGENERATION; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; TECHNOLOGY;

BIOLOGICAL MARKERS; COGNITION DISORDERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 82755197084     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.09.011     Document Type: Note

References (26)

1. Bertram L. Alzheimer's genetics in the GWAS era: a continuing story of "replications and refutations". Curr. Neurol. Neurosci. Rep. 2011, 11:246-253.
2. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
3. Brewis I.A., Brennan P. Proteomics technologies for the global identification and quantification of proteins. Adv. Protein Chem. Struct. Biol. 2010, 80:1-44.
4. Collins F. Has the revolution arrived?. Nature 2010, 464:674-675.
5. Dougherty E. Twists of fate. Harv. Med. 2010, 83:12-19.
6. Edenberg H.J., Liu Y. Laboratory methods for high-throughput genotyping. Cold Spring Harb. Protoc. 2009, pdb.top62, 20150074.
7. Feero W.G., Guttmacher A.E., Collins F.S. Genomic medicine - an updated primer. N. Engl. J. Med. 2010, 362:2001-2011.
8. Gottesman I.I., Shields J. Genetic theorizing and schizophrenia. Br. J. Psychiatry 1973, 122:15-30.
9. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213.
10. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5:e13950.
11. Jostins L., Barrett J.C. Genetic risk prediction in complex disease. Hum. Mol. Genet. 2011, 20. R182-8.
12. Kim S., Swaminathan S., Shen L., Risacher S.L., Nho K., Foroud T., Shaw L.M., Trojanowski J.Q., Potkin S.G., Huentelman M.J., Craig D.W., DeChairo B.M., Aisen P.S., Petersen R.C., Weiner M.W., Saykin A.J. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79.
13. Kupfer D.J., Regier D.A. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am. J. Psychiatry 2011, 168:672-674.
14. Lambert J.-C., Grenier-Boley B., Chouraki V., Heath S., Zelenika D., Fievet N., Hannequin D., Pasquier F., Hanon O., Brice A., Epelbaum J., Berr C., Dartigues J.-F., Tzourio C., Campion D., Lathrop M., Amouyel P. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J. Alzheimers Dis. 2010, 20:1107-1118.
15. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
16. Lill, C.M., Bertram, L. Towards unveiling the genetics of neurodegenerative diseases. Semin. Neurol. (in press).
17. Mardis E.R. The $1,000 genome, the $100,000 analysis?. Genome Med. 2010, 2:84.
18. McCarthy M.I., Abecasis G.R., Cardon L.R., Goldstein D.B., Little J., Ioannidis J.P.A., Hirschhorn J.N. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 2008, 9:356-369.
19. Mihaescu R., Moonesinghe R., Khoury M.J., Janssens A.C.J. Predictive genetic testing for the identification of high-risk groups: a simulation study on the impact of predictive ability. Genome Med. 2011, 3:51.
20. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005, 1:55-66.
21. Niccol A. GATTACA 1997, Sony Pictures.
22. Offit K. Personalized medicine: new genomics, old lessons. Hum. Genet. 2011, 130:3-14.
23. Schjeide B.-M.M., Schnack C., Lambert J.-C., Lill C.M., Kirchheiner J., Tumani H., Otto M., Tanzi R.E., Lehrach H., Amouyel P., von Arnim C.A.F., Bertram L. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch. Gen. Psychiatry 2011, 68:207-213.
24. Suk K. Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. Expert Rev. Proteomics 2010, 7:263-274.
25. Trojanowski J.Q., Hampel H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog. Neurobiol. 2011, 95:491-495.
26. Wray N.R., Yang J., Goddard M.E., Visscher P.M. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet. 2010, 6:e1000864.